MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 406516 | Name: CCT007093
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CCT007093 is a potent PPM1D inhibitor or WIP1 inhibitor that selectively reduces viability of human tumour cell lines. CCT007093 enhances liver regeneration and increases the survival rate of mice after major hepatectomy. CT007093 treatment appeares to promote apoptosis in breast cancer cells and skin transformed keratinocytes that ectopically expressed Wip1, demonstrating that the effect of CCT007093 differs based on the level of Wip1 expression. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.

Chemical Structure

CCT007093
CCT007093
CAS#176957-55-4

Theoretical Analysis

MedKoo Cat#: 406516

Name: CCT007093

CAS#: 176957-55-4

Chemical Formula: C15H12OS2

Exact Mass: 272.0330

Molecular Weight: 272.39

Elemental Analysis: C, 66.14; H, 4.44; O, 5.87; S, 23.54

Price and Availability

Size Price Availability Quantity
100mg USD 450.00 2 Weeks
200mg USD 750.00 2 Weeks
500mg USD 1,250.00 2 Weeks
1g USD 2,150.00 2 Weeks
2g USD 3,150.00 2 Weeks
5g USD 4,650.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
CCT007093; CCT-007093; CCT 007093;
IUPAC/Chemical Name
(2E,5E)-2,5-Bis(2-thienylmethylene)-cyclopentanone.
InChi Key
KPFZCKDPBMGECB-WGDLNXRISA-N
InChi Code
InChI=1S/C15H12OS2/c16-15-11(9-13-3-1-7-17-13)5-6-12(15)10-14-4-2-8-18-14/h1-4,7-10H,5-6H2/b11-9+,12-10+
SMILES Code
O=C1/C(CC/C1=C\C2=CC=CS2)=C/C3=CC=CS3
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        
Product Data
Product Data
Instruction
View handling instruction
Biological target:
CCT007093 is an effective protein phosphatase 1D (PPM1D Wip1) inhibitor.
In vitro activity:
CCT007093 treatment appeared to promote apoptosis in breast cancer cells and skin transformed keratinocytes that ectopically expressed Wip1, demonstrating that the effect of CCT007093 differs based on the level of Wip1 expression. Reference: J Dermatol Sci. 2014 Feb;73(2):125-34. https://linkinghub.elsevier.com/retrieve/pii/S0923-1811(13)00310-1
In vivo activity:
It was examined whether Wip1 inhibitor could enhance LR in vivo. The ILBW was significantly increased in CCT007093-treated mice, compared to vehicle-treated mice, and the level of PCNA was also significantly increased in liver of CCT007093-treated mice at 36, 48, and 72 hours post-PHx (Fig. 6A,B), suggesting that inhibition of Wip1 promoted LR after PHx. Next, we explored whether the increased LR after CCT007093 treatment significantly improved survival in mice after major hepatectomy (80% hepatectomy). By 72 hours after major hepatectomy, the survival rate in the vehicle-treated group was less than 40%, whereas 80% of mice survived in the CCT007093-treated group. Kaplan-Meier's analysis showed that CCT007093 treatment significantly increased the survival rate of mice after major hepatectomy (Fig. 6C). Pearson's correlation analysis revealed a significant positive correlation between ILBW and survival time (Pearson's r = 0.76; P = 0.02; Fig. 6D), suggesting that the increased survival rate was a result of the enhanced LR in CCT007093-treated mice after major hepatectomy. The number and percentage of neutrophils, lymphocytes, and monocytes of peripheral blood in CCT007093-treated mice had no differences, compared to the control group (Supporting Fig. 6A,B). H&E staining showed normal liver histology in CCT007093-treated mice at 36 hours post-PHx (Supporting Fig. 6C). No inflammatory cell was detected in CCT007093-treated and control mice at 36 hours post-PHx (Supporting Fig. 6C). We also examined the necrosis and apoptosis levels by H&E and terminal deoxynucleotidyl transferase dUTP nick end labeling staining, as well as western blotting analysis of cleaved caspase-3 and rip1. The data showed that necrosis and apoptosis levels were comparable between Wip1−/− and Wip1+/+ livers at 24 and 48 hours after major hepatectomy (Supporting Fig. 6D-F). Reference: Hepatology. 2015 Jun;61(6):2030-41. https://doi.org/10.1002/hep.27755
Solvent mg/mL mM
Solubility
DMSO 2.8 10.28
DMF 3.3 12.23
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 272.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Lee JS, Park JR, Kwon OS, Kim H, Fornace AJ Jr, Cha HJ. Off-target response of a Wip1 chemical inhibitor in skin keratinocytes. J Dermatol Sci. 2014 Feb;73(2):125-34. doi: 10.1016/j.jdermsci.2013.09.003. Epub 2013 Sep 13. PMID: 24126074.
In vivo protocol:
1. Zhang L, Liu L, He Z, Li G, Liu J, Song Z, Jin H, Rudolph KL, Yang H, Mao Y, Zhang L, Zhang H, Xiao Z, Ju Z. Inhibition of wild-type p53-induced phosphatase 1 promotes liver regeneration in mice by direct activation of mammalian target of rapamycin. Hepatology. 2015 Jun;61(6):2030-41. doi: 10.1002/hep.27755. Epub 2015 Mar 25. PMID: 25704606.
1: Lee JS, Park JR, Kwon OS, Kim H, Fornace AJ Jr, Cha HJ. Off-target response of a Wip1 chemical inhibitor in skin keratinocytes. J Dermatol Sci. 2014 Feb;73(2):125-34. doi: 10.1016/j.jdermsci.2013.09.003. Epub 2013 Sep 13. PubMed PMID: 24126074. 2: Pivovarov AS, Murzina GB, Tret'iakova MS, Makhnovskiĭ DA. [Role of serine/threonine and tyrosine protein phosphatases in command Helix lucorum neurons at the cellular correlate of habituation]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2013 Mar-Apr;63(2):256-68. Russian. PubMed PMID: 23866612. 3: Buss MC, Read TA, Schniederjan MJ, Gandhi K, Castellino RC. HDM2 promotes WIP1-mediated medulloblastoma growth. Neuro Oncol. 2012 Apr;14(4):440-58. doi: 10.1093/neuonc/nos001. Epub 2012 Feb 29. PubMed PMID: 22379189; PubMed Central PMCID: PMC3309853. 4: Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res. 2010;12(3):R41. doi: 10.1186/bcr2595. Epub 2010 Jun 24. PubMed PMID: 20576088; PubMed Central PMCID: PMC2917036. 5: Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 2009 Apr 1;15(7):2269-80. doi: 10.1158/1078-0432.CCR-08-2403. Epub 2009 Mar 17. PubMed PMID: 19293255.